Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 6/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 6/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 5/20 | 1.00 |
| ▸ | IRAK1 | P51617 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 0.69 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.67 |
| ▸ | KIT | P10721 | 2/20 | 0.67 |
| ▸ | KDR | P35968 | 2/20 | 0.67 |
| ▸ | ABL1 | P00519 | 6/20 | 0.61 |
| ▸ | BCR | P11274 | 6/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.61 |
| ▸ | SRC | P12931 | 3/20 | 0.61 |
| ▸ | PRKCA | P17252 | 3/20 | 0.61 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.61 |
| ▸ | CDK7 | P50613 | 2/20 | 0.61 |
| ▸ | CCNH | P51946 | 2/20 | 0.61 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.61 |
| ▸ | PRKCG | P05129 | 1/20 | 0.61 |
| ▸ | PRKCB | P05771 | 1/20 | 0.61 |
| ▸ | PRKCH | P24723 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14979768 | 1.00 | MAPK8 (1.00) | MAPK8MAPK9MAPK10IRAK1EGFR | |
| SCHEMBL29406102 | 1.00 | MAPK8 (1.00) | MAPK8MAPK9MAPK10IRAK1EGFR | |
| SCHEMBL29403577 | 1.00 | MAPK8 (1.00) | MAPK8MAPK9MAPK10IRAK1EGFR | |
| SCHEMBL14979764 | 1.00 | MAPK8 (1.00) | MAPK8MAPK9MAPK10IRAK1EGFR | |
| SCHEMBL29416038 | 0.93 | MAPK8 (1.00) | MAPK8MAPK9MAPK10IRAK1EGFR | |
| SCHEMBL14979773 | 0.93 | MAPK8 (1.00) | MAPK8MAPK9MAPK10IRAK1EGFR | |
| SCHEMBL16344699 | 0.92 | MAPK8 (1.00) | MAPK8MAPK9MAPK10IRAK1EGFR | |
| SCHEMBL30290728 | 0.92 | MAPK8 (1.00) | MAPK8MAPK9MAPK10IRAK1EGFR | |
| SCHEMBL14979761 | 0.92 | MAPK8 (1.00) | MAPK8MAPK9MAPK10IRAK1EGFR | |
| SCHEMBL29403872 | 0.92 | MAPK8 (1.00) | MAPK8MAPK9MAPK10IRAK1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210324031-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2021-10-21 | — | — | US | claimed |
| US-12435116-B2 | Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome | LINK THERAPEUTICS, LLC | 2025-10-07 | — | — | US | disclosed |
| US-20220064249-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING INSULIN RESISTANCE, TYPE 2 DIABETES AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2022-03-03 | — | — | US | disclosed |
| US-20210324031-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435116-B2 | Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome | INSR, IRS1, INSRR | MAPK8 1803/4885MAPK9 2549/4885MAPK10 2203/4885 |
| US-20210324031-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME | LIPE, GPR119, FABP4 | MAPK8 1958/4885MAPK9 2843/4885MAPK10 2119/4885 |
| US-20220064249-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING INSULIN RESISTANCE, TYPE 2 DIABETES AND METABOLIC SYNDROME | INSR, IRS1, INSRR | MAPK8 1803/4885MAPK9 2549/4885MAPK10 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.